Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Charalambos Christofilakis"'
Autor:
Nikolaos Xenidis, Christos Latoufis, Nikolaos Androulakis, Charalambos Kouroussis, Pavlos Papakotoulas, Aristidis Polyzos, Helen Toufexi, Anna Potamianou, V. Georgoulias, Charalambos Christofilakis
Publikováno v:
Oncology. 69:348-353
Cisplatin or carboplatin plus paclitaxel is considered the standard first-line treatment in ovarian cancer. Attempts to maximize tumor cytoreduction with first-line chemotherapy by incorporating new promising agents led to sequential drug administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9899136c6e78b467f65e77fb67d486c9
https://doi.org/10.1159/000089767
https://doi.org/10.1159/000089767
Autor:
Charalambos Kouroussis, Michael Toumbis, Charalambos Christofilakis, Emilia Tsaroucha, Konstantinos N. Syrigos, M. Agelidou, A. Agelidou, Nicolaos Ziras, Vassilis Georgoulias, Nikolaos Samaras, Athanasios Alegakis, Alexandros Ardavanis, Pavlos Papakotoulas, Vassilis Chandrinos, Aristidis Polyzos
Publikováno v:
Journal of Clinical Oncology. 22:2602-2609
Purpose To compare the overall survival (OS) of patients with advanced non–small-cell lung cancer (NSCLC) treated with docetaxel plus cisplatin (DC) or docetaxel (D) alone. Patients and Methods Chemotherapy-naïve patients with advanced/metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53125a9e6c9b279a963591b20c828a4d
https://doi.org/10.1200/jco.2004.11.004
https://doi.org/10.1200/jco.2004.11.004
Autor:
Xenofon Papanicolaou, George Margaritis, Charalambos Christofilakis, George Giannakos, Isaak Michaelidis, Dimitrios T. Trafalis
Publikováno v:
International journal of urology : official journal of the Japanese Urological Association. 12(8)
Cholestasis, as a paraneoplastic syndrome, has been well described in patients with malignant lymphohyperplastic diseases and renal cell cancer. Non-metastatic nephrogenic hepatic dysfunction syndrome without jaundice has often been described in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4235fc897a6db6046fa0711628046871
https://pubmed.ncbi.nlm.nih.gov/16174051
https://pubmed.ncbi.nlm.nih.gov/16174051
Autor:
Anna, Potamianou, Nikolaos, Androulakis, Pavlos, Papakotoulas, Helen, Toufexi, Christos, Latoufis, Charalambos, Kouroussis, Charalambos, Christofilakis, Nikolaos, Xenidis, Vassilios, Georgoulias, Aristidis, Polyzos
Publikováno v:
Oncology. 69(4)
Cisplatin or carboplatin plus paclitaxel is considered the standard first-line treatment in ovarian cancer. Attempts to maximize tumor cytoreduction with first-line chemotherapy by incorporating new promising agents led to sequential drug administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::50a2a09b3ce1e99ce91ffb53a6296cea
https://pubmed.ncbi.nlm.nih.gov/16293974
https://pubmed.ncbi.nlm.nih.gov/16293974